Literature DB >> 27520517

Childhood Epilepsy : Current Therapeutic Recommendations.

J T Gilman1,2, M Duchowny1.   

Abstract

The pharmacotherapy of epilepsy in children must account for a number of specific issues. The nature of epileptic disorders found in children differs from that in adults. For example, epilepsies of childhood are more likely to be developmentally or genetically based than those found in adults. Children also differ from adults in indications for antiepileptic drugs. Indeed, some types of childhood epilepsy do not require specific pharmacological treatment since prognosis is often excellent without therapy. This is especially true for children who are neurologically nonnal and those with benign epilepsy syndromes that have a characteristic electroclinical presentation, such as febrile seizures. In contrast, children with evidence of brain damage or those with serious epilepsy syndromes must be treated promptly.Once it has been decided that treatment is necessary, the choice of treatment should be based on a comparison of efficacy and tolerability of individual antiepileptic agents. The spectrum of toxicity is often different in younger patients from that in adults, and adverse effects that are acceptable in adults may be cause for discontinuation of therapy in children. Intellectual, cognitive and behavioural toxicity are particularly unacceptable.Establishing sustained therapeutic serum concentrations in children also requires specific attention. Rapid gastrointestinal transit times and interactions with milk and infant formulas may pose special management problems. Toxic metabolites of antiepileptic drugs are frequently produced in children. This can lead to drug hypersensitivity and other possible conditions, such as valproic acid (sodium valproate)-induced hepatotoxicity.Unless specific paediatric data are obtained, recommendations for the treatment of epilepsies in children will continue to be based on studies in adults and on anecdotal observations. Given the high prevalence and significant morbidity of childhood epilepsies, further studies of treatments are urgently needed.

Entities:  

Year:  1994        PMID: 27520517     DOI: 10.2165/00023210-199401030-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  72 in total

1.  Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations.

Authors:  O Eeg-Olofsson; H L Nilsson; B Tonnby; J Arvidsson; P A Grahn; H Gylje; C Larsson; L Norén
Journal:  J Child Neurol       Date:  1990-04       Impact factor: 1.987

Review 2.  The treatable epilepsies. (First of Two Parts).

Authors:  A V Delgado-Escueta; D M Treiman; G O Walsh
Journal:  N Engl J Med       Date:  1983-06-23       Impact factor: 91.245

3.  Long-term follow-up of absence seizures.

Authors:  S Sato; F E Dreifuss; J K Penry; D D Kirby; Y Palesch
Journal:  Neurology       Date:  1983-12       Impact factor: 9.910

4.  Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Canadian Clobazam Cooperative Group.

Authors: 
Journal:  Epilepsia       Date:  1991 May-Jun       Impact factor: 5.864

Review 5.  Felbamate.

Authors:  N M Graves
Journal:  Ann Pharmacother       Date:  1993-09       Impact factor: 3.154

6.  Risk of seizure recurrence following a first unprovoked seizure in childhood: a prospective study.

Authors:  S Shinnar; A T Berg; S L Moshé; M Petix; J Maytal; H Kang; E S Goldensohn; W A Hauser
Journal:  Pediatrics       Date:  1990-06       Impact factor: 7.124

7.  Fatal liver failure in 16 children with valproate therapy.

Authors:  D Scheffner; S König; I Rauterberg-Ruland; W Kochen; W J Hofmann; S Unkelbach
Journal:  Epilepsia       Date:  1988 Sep-Oct       Impact factor: 5.864

Review 8.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

9.  Benign childhood epilepsy with occipital paroxysms: a 15-year prospective study.

Authors:  C P Panayiotopoulos
Journal:  Ann Neurol       Date:  1989-07       Impact factor: 10.422

10.  A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group.

Authors:  R H Mattson; J A Cramer; J F Collins
Journal:  N Engl J Med       Date:  1992-09-10       Impact factor: 91.245

View more
  1 in total

Review 1.  Pharmacokinetic considerations in the treatment of childhood epilepsy.

Authors:  Jamie T Gilman; Michael Duchowny; Ana E Campo
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.